Indian Accounting Research Analyst, Trudence Capital Advisors

Nitin Mangal

Nitin Mangal is a Research Analyst with more than 15 years of experience in Indian equities. He is Pioneer of Corporate Governance and Accounting Research in Indian Market and has successfully developed product for Institutional Investors named as "Analysis Beyond Consensus" during his association with Edelweiss Securities Ltd, Mumbai. Later during the career, he has worked with Veritas Investment Research Corporation, Canada as Asia Consultant covering Indian and US equities. He has been profiled by leading financial newspapers such as Wall Street Journal, Business Standard etc

Indian Accounting Research Analyst

COVID-19: A Brutal Lesson in Sustainability and Systemic ESG Risk

Covid-19 Action Plan: Too Little Too Late

Thematic (Sector/Industry)

India Pharmaceuticals, biotechnology and life sciences / Thematic (Sector/Industry)

<p>Corona Virus shadows are glooming all over the world, and these fears have just begun. As a major highlight of 2020, the virus has conquered the financial streets as well resulting in bloodbaths across all the major indices. However, one industry for which a major threat awaits to prolong is the Indian Pharmaceuticals, whose supply chain is likely going to shred into major disruptions.</p>

Corona Virus shadows are glooming all over the world, and these fears have just begun. As a major highlight of 2020, the virus has conquered the financial streets as well resulting in bloodbaths across all the major indices. However, one industry for which a major threat awaits to prolong is the Indian Pharmaceuticals, whose supply chain is likely going to shred into major disruptions.

COVID-19 : A Viral Threat to Pharma Supply Chain